Membranous nephropathy represents a leading etiology of nephrotic syndrome across adult populations worldwide. The newly released 2026 clinical guideline standardizes membranous nephropathy management to optimize patient outcomes. By incorporating the Grading of Recommendations Assessment, Development and Evaluation system, this framework delivers transparent practice suggestions. Consequently, clinicians gain practical guidance to refine diagnostic workflows and therapeutic decisions.

Evolving Diagnostic Paradigms and Antigen Identification

Historically, physicians relied almost entirely on invasive percutaneous renal biopsy to identify glomerular capillary wall thickening. However, major scientific breakthroughs have uncovered circulating autoantibodies against specific podocyte antigens. Approximately seventy to eighty percent of primary cases exhibit autoantibodies against the M-type phospholipase A2 receptor. Furthermore, researchers have characterized additional target antigens, including thrombospondin type-1 domain-containing 7A and neural epidermal growth factor-like 1 protein.

These serological discoveries have fundamentally reshaped everyday nephrology practice. Consequently, non-invasive biomarker assays now allow clinicians to confirm diagnosis when clinical presentations remain unambiguous. In addition, serological testing facilitates rapid differentiation between primary forms and secondary causes such as malignancy, systemic lupus erythematosus, or chronic hepatitis B infection. Nevertheless, kidney biopsy retains substantial value for ambiguous cases or when unexplained renal function decline occurs. Histological evaluation accurately reveals underlying tubulointerstitial fibrosis, vascular injury, and concurrent crescentic lesions. Therefore, modern diagnostic protocols successfully combine cutting-edge serology with traditional histopathology to establish early and precise diagnoses.

Risk Stratification in Membranous Nephropathy Management

Accurate risk stratification remains essential before clinicians start toxic immunosuppressive regimens. Because approximately one-third of individuals achieve spontaneous remission, universal early immunosuppression exposes low-risk patients to unnecessary adverse effects. Therefore, the 2026 guideline strongly advocates systematic clinical and serological risk categorization. Clinicians stratify patients into low, moderate, high, or very high risk groups based on specific clinical parameters.

Key stratification variables include urinary protein excretion, serum albumin concentrations, glomerular filtration rates, and circulating anti-PLA2R antibody titers. Low-risk patients demonstrate preserved kidney function and low baseline proteinuria. Conversely, high-risk individuals exhibit persistent massive proteinuria exceeding eight grams daily, declining renal function, or high antibody titers. Furthermore, dynamic monitoring of antibody titers provides exceptional prognostic insight. A steady decline in anti-PLA2R antibody levels usually signals impending immunological remission long before clinical proteinuria resolves. Conversely, persistently elevated or escalating titers portend disease progression and progressive nephron loss. Consequently, clinicians must evaluate dynamic antibody trajectories to guide individualized therapeutic timelines effectively.

Comprehensive Supportive Measures for All Patients

Supportive therapy forms the foundational pillar of management across all risk strata. Clinicians should implement maximum tolerated renin-angiotensin-aldosterone system inhibition using either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. In addition, sodium-glucose cotransporter-2 inhibitors now offer compelling benefits in reducing glomerular hyperfiltration and stabilizing long-term renal function. Clinicians must simultaneously reinforce strict dietary sodium restriction below two grams daily.

Furthermore, aggressive blood pressure control remains vital to attenuate glomerular capillary wall stress. Clinicians should target systolic blood pressure below one hundred twenty millimeters of mercury when tolerated. Dyslipidemia represents another common metabolic disturbance in nephrotic syndrome that warrants statin therapy. Moreover, nephrotic patients face substantial risks of venous thromboembolism, especially deep vein thrombosis and renal vein thrombosis. Hypoalbuminemia below twenty to twenty-five grams per liter severely amplifies hypercoagulability. Therefore, the guideline recommends individualized prophylactic anticoagulation for high-risk patients who maintain low bleeding risk. Clinicians should also administer pneumococcal and annual influenza vaccinations to prevent debilitating infections. Through these combined supportive interventions, physicians protect microvascular architecture and prevent avoidable systemic complications.

Targeted Immunosuppressive Strategies and Biologics

When patients display moderate to very high progression risk, immunosuppressive therapy becomes mandatory. Historically, cyclical alternating regimens of corticosteroids and alkylating agents like cyclophosphamide induced robust remissions. However, alkylators carry considerable toxicities, including gonadal failure, secondary malignancies, and severe opportunistic infections. Consequently, modern therapy increasingly favors safer, targeted biological agents.

The 2026 guideline highlights rituximab, a monoclonal antibody targeting CD20-positive B cells, as a primary first-line therapeutic option. Rituximab selectively depletes antibody-producing B-cell clones, which halts the production of nephritogenic anti-PLA2R autoantibodies. For moderate-risk patients, rituximab monotherapy frequently achieves sustained immunological and clinical remissions. Alternatively, calcineurin inhibitors, such as tacrolimus or cyclosporine, offer an effective alternative, particularly for patients intolerant to rituximab. However, calcineurin inhibitors produce higher relapse rates upon discontinuation unless clinicians taper them very slowly. For patients with life-threatening nephrotic syndrome or rapidly declining renal function, cyclical cyclophosphamide combined with corticosteroids remains the most potent salvage regimen. Therefore, clinicians must carefully tailor immunosuppression according to individualized risk profiles, patient age, and fertility goals.

Long-Term Monitoring and Relapse Management Protocols

Long-term surveillance is crucial because membranous nephropathy follows an unpredictable, relapsing course. Clinicians should monitor urinary protein excretion, serum creatinine, and serum albumin every three months during active treatment. In addition, serial quantification of circulating anti-PLA2R antibodies provides invaluable real-time information regarding disease activity. An immunological response invariably precedes clinical proteinuria reduction by several months. Conversely, antibody reappearance reliably predicts clinical relapse before overt proteinuria recurs.

When patients experience relapses, clinicians must determine whether previous therapies achieved complete antibody clearance. If patients relapse after successful rituximab-induced remission, a repeat course of rituximab frequently re-establishes remission safely. Similarly, patients who relapse following calcineurin inhibitor withdrawal often respond well to rituximab introduction or combined maintenance protocols. Furthermore, novel therapeutic approaches are emerging for refractory cases that fail conventional immunosuppressive regimens. These investigational strategies include dual B-cell and plasma-cell targeted therapies, such as telitacicept, alongside complement pathway inhibitors. Ultimately, systematic outpatient monitoring ensures prompt therapeutic adjustments, which shields patients from cumulative drug toxicity and preserves long-term renal survival.

What role does anti-PLA2R antibody testing play in diagnosis?

Anti-PLA2R antibody testing plays a pivotal diagnostic and prognostic role in primary membranous nephropathy. Because this biomarker demonstrates exceptional clinical specificity, high circulating titers can confirm the diagnosis in patients presenting with nephrotic syndrome without immediate biopsy. Furthermore, serial antibody measurements reflect ongoing immunological activity. A rapid titer decline indicates therapeutic efficacy, whereas rising titers warn clinicians of disease persistence or impending clinical relapse.

When should clinicians initiate immunosuppressive therapy in membranous nephropathy?

Clinicians should initiate immunosuppressive therapy when patients demonstrate moderate to high risk of progressive kidney disease. This includes individuals with persistent nephrotic-range proteinuria despite three to six months of optimized supportive therapy. Additionally, physicians should immediately begin treatment if patients present with rapidly deteriorating renal function, severe debilitating nephrotic symptoms, or markedly elevated anti-PLA2R antibody levels. Low-risk patients should initially receive conservative supportive care under close watchful waiting.

Why is prophylactic anticoagulation recommended for selected patients?

Prophylactic anticoagulation is strongly recommended because membranous nephropathy carries the highest risk of thromboembolic events among all glomerular diseases. Severe urinary loss of natural anticoagulant proteins, such as antithrombin III, produces a pronounced hypercoagulable state. Therefore, clinicians prescribe prophylactic anticoagulants to individuals with profound hypoalbuminemia, specifically serum albumin below twenty to twenty-five grams per liter, provided bleeding risk remains low. This protective intervention effectively prevents life-threatening pulmonary embolism and venous thrombosis.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. undefined undefined et al. [Guideline for the diagnosis, treatment and management of membranous nephropathy (2026 edition)]. Zhonghua Yi Xue Za Zhi. 2026 Sep 23. doi: 10.3760/cma.j.cn112137-20260808-01958. PMID: 42773989.
2. Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.
3. Ronco P, Beck L, Debiec H, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7(1):69.